Whom should we treat with novel agents? Specific indications for specific and challenging populations

Abstract

A relative wealth of new therapies for acute myeloid leukemia (AML) have led to a rapid shift in treatment paradigms for this disease. Understanding whom, when, and how to treat is more complex than ever before. Here we explore whom to treat with these available new therapies, focusing on special patient populations that include older adults, those with relapsed disease, and those with TP53-mutated AML. These high-risk subgroups are some of the most challenging to care for, but novel treatments are providing them with new hope.

Trial registration: ClinicalTrials.gov NCT03471260.

Conflict of interest statement

Lindsay Wilde: no conflicts to disclose.

Margaret Kasner: research funding: Astellas, Diachi, Gilead, Jazz, Telios, Ono, Otsuka, Pfizer; honoraria: Kite, Jazz, Ono.

Copyright © 2021 by The American Society of Hematology.

Figures

Graphical abstract

Figure 1.

Factors leading to a poor prognosis in older AML patients.

Figure 2.

Algorithm for the treatment of newly diagnosed AML in the older patient.

Figure 3.

Algorithm for the treatment of relapsed older AML patients.